PATEL, AKASH M. D.
Dermatology · NPI 1811955792 · GARLAND, TX
PATEL, AKASH is a Dermatology in GARLAND, TX, a member of 2 medical groups, who billed 36 distinct codes to Medicare Part B in 2024.
Groups: PDP OF TEXAS, PLLC (PLANO, TX) · UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS (DALLAS, TX) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group
Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒
Provider overview · all codes · CY2024
All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.
Procedures billed to Medicare Part B (2024)
Medicare Part B FFS · CY2024 · as published by CMS| Code | Description | Services | Beneficiary-episodes | Avg charge | Avg Medicare payment |
|---|---|---|---|---|---|
| 17003 | Destruction of precancer skin growth, 2-14 growths | premium | premium | premium | premium |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| 17110 | Destruction of skin growth, 1-14 growths | premium | premium | premium | premium |
| 17000 | Destruction of precancer skin growth, 1 growth | premium | premium | premium | premium |
| 17004 | Destruction of precancer skin growth, 15 or more growths | premium | premium | premium | premium |
| 99213 | Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | premium | premium | premium | premium |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | premium | premium | premium | premium |
| 11102 | Biopsy of related skin growth, first growth | premium | premium | premium | premium |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | premium | premium | premium | premium |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | premium | premium | premium | premium |
| 11103 | Biopsy of related skin growth, each additional growth | premium | premium | premium | premium |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | premium | premium | premium | premium |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | premium | premium | premium | premium |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | premium | premium | premium | premium |
| 11307 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | premium | premium | premium | premium |
| 11306 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | premium | premium | premium | premium |
| 17273 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | premium | premium | premium | premium |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | premium | premium | premium | premium |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | premium | premium | premium | premium |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | premium | premium | premium | premium |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | premium | premium | premium | premium |
| 11312 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | premium | premium | premium | premium |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | premium | premium | premium | premium |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | premium | premium | premium | premium |
| 69100 | Biopsy of ear | premium | premium | premium | premium |
| 99203 | New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more | premium | premium | premium | premium |
| 13122 | Complicated repair of wound of scalp, arms, or legs, each additional 5.0 cm or less | premium | premium | premium | premium |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | premium | premium | premium | premium |
| 11200 | Removal of skin tag, 1-15 skin tags | premium | premium | premium | premium |
| 11901 | Injection into skin growth, more than 7 growths | premium | premium | premium | premium |
| 11303 | Shaving of skin growth of body, arms, or legs, more than 2.0 cm | premium | premium | premium | premium |
| 11623 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | premium | premium | premium | premium |
| 17111 | Destruction of skin growth, 15 or more growths | premium | premium | premium | premium |
| 10061 | Complicated or multiple drainage of skin abscess | premium | premium | premium | premium |
| 17283 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 2.1-3.0 cm | premium | premium | premium | premium |
| 11643 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 2.1-3.0 cm | premium | premium | premium | premium |
These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.